Hyperlipidemia is a major public health problem throughout the world. Consequent atherogenic disorders occupied the first place in five major killer diseases due to high mortality and high morbidity in the world.
Adouble blind, placebo controlled, randomized clinical trial was conducted to test the safety and efficacy of a unani formulation in subjects with hyperlipidaemia. Unani formulation significantly improved lipid profile as compared to placebo. During 60 days therapy, no noticable adverse/side effectes were detected in both treatment groups